Core Insights - Outset Medical, Inc. reported its financial results for Q4 and the full year 2025, highlighting a strong foundation for growth and a differentiated platform in the dialysis market [3][4]. Financial Performance - Q4 2025 revenue was $28.9 million, a decrease of 2% from $29.5 million in Q4 2024. Product revenue was $19.9 million, down from $21 million, while service and other revenue increased by 6% to $9 million [4][9]. - For the full year 2025, total revenue reached $119.5 million, a 5% increase from $113.7 million in 2024. Product revenue also grew by 5% to $84.8 million [9][10]. - Recurring revenue from Tablo consumables and services was $22.5 million in Q4 and grew 6% for the year to $88.7 million [4][9]. Profitability Metrics - Gross profit for Q4 was $12.2 million, up 14% from $10.7 million in Q4 2024, with a gross margin of 42.4%, compared to 36.5% in the prior year [5][11]. - The full year gross margin improved to 39.1%, up from 33.9% in 2024, with a non-GAAP gross margin of 39.6% [11][12]. Operating Expenses - Operating expenses in Q4 2025 were $29.9 million, an 8% decline from $32.6 million in Q4 2024, driven by cost reductions [6][12]. - For the full year, operating expenses totaled $113.5 million, down from $151.9 million in 2024 [12][13]. Net Loss - The net loss for Q4 was $19.5 million, an improvement from a net loss of $25.6 million in Q4 2024. On a non-GAAP basis, the net loss was $15.1 million compared to $19.3 million in the prior year [7][13]. - The full year net loss was $81.7 million, significantly reduced from $128 million in 2024, with a non-GAAP net loss of $65.4 million [13][14]. Cash Position - As of December 31, 2025, total cash, including restricted cash and short-term investments, was $173 million [8][28]. Future Guidance - For 2026, Outset provided revenue guidance of $125 million to $130 million, representing a 5% to 9% increase over 2025, with non-GAAP gross margin expected in the low to mid-40% range [14].

Company Overview - Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience with innovative technology [4] - The company's flagship product, the Tablo® Hemodialysis System, is FDA-cleared for use in various healthcare settings, from hospitals to home care [4] - Tablo integrates water purification and on-demand dialysate production into a single system, enhancing operational efficiency and patient care [4] Financial Results Announcement - Outset Medical will release its financial results for the fourth quarter and full-year 2025 on February 11, 2026, after market close [1] - A conference call will be held on the same day at 1:30 p.m. Pacific time to discuss these results [2][3] Conference Call Details - Participants interested in the conference call must register online to receive dial-in numbers and a unique pin [3] - A live and archived webcast of the conference call will be available on the company's investor relations website [3]

Core Insights - Outset Medical, Inc. reported unaudited revenue for Q4 and fiscal year 2025, highlighting a 5% increase in annual revenue to approximately $119.5 million compared to $113.7 million in 2024 [8] - The company has appointed Karen N. Prange to its board of directors, bringing extensive experience in commercial operations and strategy [4][5][6] - Outset Medical aims to leverage its innovative technology to enhance patient care outcomes while reducing costs and complexity in dialysis [3] Financial Performance - Q4 revenue reached approximately $28.9 million, contributing to the total revenue of approximately $119.5 million for 2025 [8] - The year-end cash position, including restricted cash and short-term investments, totaled $173 million, with net cash used in operations below $50 million in 2025, a significant decrease from $116 million in 2024 [8] Company Developments - Outset Medical has established a strong backlog and a growing pipeline of opportunities as it enters 2026 [3] - The company has enabled over 1,000 care sites to insource dialysis, performing roughly 1 million treatments annually, with a cumulative total of over 3 million treatments on its Tablo system [8] - The appointment of Karen Prange is expected to enhance the board's capabilities in navigating growth opportunities in the acute-care setting [6]

Company Overview - Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience with innovative technology [3] - The company’s flagship product, the Tablo® Hemodialysis System, is FDA-cleared for use in various settings, from hospitals to home care [3] - Tablo integrates water purification and on-demand dialysate production into a single system, enhancing operational efficiency and patient care [3] Key Presentation Details - Chair & CEO Leslie Trigg will present at the 44th annual J.P. Morgan Healthcare conference on January 14, 2026, at 4:30 p.m. Pacific time [1] - A live and archived webcast of the presentation will be available on the Outset Medical website [2] Market Impact - The Tablo system is currently trusted by over 1,000 healthcare facilities in the U.S. and has facilitated millions of treatments by thousands of nurses [3] - Outset Medical aims to empower healthcare providers to establish in-house dialysis programs, leading to improved operational, clinical, and financial outcomes [3]

Core Insights - Outset Medical, Inc. has revised its 2025 revenue guidance to a range of $115 million to $120 million, down from a previous estimate of $122 million to $126 million [3][11] - The company reported a third-quarter revenue of $29.4 million, reflecting a 3% increase compared to $28.7 million in the same quarter of 2024 [5][9] - Operating expenses decreased by 19% year-over-year, totaling $27.4 million, as the company streamlined operations to accelerate its path to profitability [7][9] Financial Performance - Product revenue for the third quarter was $20.6 million, slightly up from $20.3 million in the prior year, while service and other revenue increased by 6% to $8.9 million [5][9] - Gross profit rose to $11.6 million, an 18% increase from $9.8 million in the third quarter of 2024, with a gross margin of 39.4%, up from 34.3% [6][9] - The net loss for the quarter was $17.8 million, an improvement from a net loss of $27.9 million in the same period last year [8][9] Cash Flow and Guidance - The company expects to use less than $50 million in cash for 2025, a significant reduction from over $100 million used in 2024 [3][11] - As of September 30, 2025, total cash, including restricted cash and short-term investments, was $182 million [10][25] - The non-GAAP gross margin guidance remains unchanged, still expected to be in the high-30% range [3][11] Market Demand and Strategy - Hospital demand for Outset's technology is growing due to its clinical, operational, and financial benefits [4] - The company is in the final stages of closing several large sales opportunities, which are now expected to finalize in the fourth quarter of 2025 and early 2026 [4]

Core Insights - Outset Medical, Inc. has announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, highlighting the effectiveness of their technology in reducing the cost and complexity of dialysis [1][5] - The findings will be presented at the American Society of Nephrology's Kidney Week 2025, which is attended by over 12,000 professionals globally, emphasizing the significance of these results in the field of kidney care [2] Group 1: Research Findings - The studies indicate that insourcing dialysis services can elevate the standard of care in hospitals, providing both clinical benefits and significant cost savings [2] - Data from a large hospital in Florida showed a 94% reduction in serious cardiac or respiratory events and a sustained reduction in central-line bloodstream infections over five years [5] - A high nurse retention rate of over 95% and strong staff satisfaction were reported, alongside a strong return on investment within the first two years of operation [5] Group 2: Clinical Effectiveness - Data from 1 million Tablo treatments across more than 600 facilities supports the clinical effectiveness of insourced dialysis in achieving rigorous treatment goals [5] - Over 99% achievement of treatment goals was noted in 10,000 treatments prescribed for more than 23 hours, performed at approximately 150 hospitals, with minimal interruptions [5] Group 3: Technology Overview - The Tablo Hemodialysis System is designed to reduce the cost and complexity of dialysis, integrating water purification and on-demand dialysate production into a single system [6] - The system is FDA-cleared for use in both hospital and home settings, indicating its versatility and broad application [5][6] - Outset Medical aims to redefine kidney care through innovation and a commitment to improving patient and provider outcomes [6]

Core Insights - Outset Medical, Inc. will release its financial results for Q3 2025 on November 10, 2025, after market close [1] - A conference call will be held on the same day at 1:30 p.m. Pacific time to discuss the financial and operating results [2][3] Company Overview - Outset Medical is a medical technology company focused on transforming the dialysis experience with its innovative Tablo® Hemodialysis System, which is FDA-cleared for use in various healthcare settings [4] - The Tablo system integrates water purification and on-demand dialysate production, facilitating a seamless connection with Electronic Medical Record systems and a proprietary data analytics platform [4] - The company aims to empower healthcare providers to establish in-house dialysis programs, improving operational, clinical, and financial outcomes [4]

Core Insights - Outset Medical, Inc. reported a strong financial performance for Q2 2025, with revenue reaching $31.4 million, a 15% increase from $27.4 million in Q2 2024, driven by a 20% rise in product revenue [4][10] - The company is focused on transforming its commercial organization and has seen growing demand for its Tablo system, which offers clinical and operational benefits [3][10] - Operating expenses decreased by 29% year-over-year, reflecting the company's efforts to streamline operations and move towards profitability [6][10] Financial Performance - Total revenue for Q2 2025 was $31.4 million, up 15% from $27.4 million in Q2 2024, with product revenue at $23.1 million, a 20% increase from $19.2 million [4][10] - Gross profit increased by 21% to $11.9 million, with a gross margin of 37.8%, compared to 35.7% in the same quarter last year [5][10] - Net loss for the quarter was $18.5 million, significantly reduced from a net loss of $34.5 million in Q2 2024 [7][10] Operational Highlights - Recurring revenue from Tablo cartridges and services reached $22.5 million, an 11% increase compared to $20.2 million in the prior-year period [4][10] - The company signed a new enterprise agreement with a major national health system, expanding Tablo's access to over 100 facilities [10] - Tablo is now utilized in more than 900 acute and sub-acute sites across the U.S. [10] Future Guidance - Outset raised its 2025 revenue guidance to a range of $122 million to $126 million, up from the previous estimate of $115 million to $125 million [11] - The company anticipates a non-GAAP gross margin in the high-30% range for 2025 and expects to use less than $50 million in cash, compared to over $100 million in 2024 [11][10]

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Product Features - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Management will present at the Goldman Sachs 46th Annual Healthcare Conference on June 11, 2025, at 11:20 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website [2]

Core Viewpoint - Outset Medical, Inc. has appointed Renee Gaeta as the new Chief Financial Officer, effective immediately, as the company aims to drive growth and achieve near-term profitability [1][2]. Company Overview - Outset Medical is a medical technology company focused on reducing the cost and complexity of dialysis through its innovative Tablo® Hemodialysis System, which is FDA cleared for use in various settings [4]. - The Tablo system integrates water purification and on-demand dialysate production, allowing for flexible dialysis delivery and operational simplification for providers [4]. Leadership Appointment - Renee Gaeta brings extensive financial and leadership experience from her previous roles as CFO at Shockwave Medical and Eko Health, among others [2][3]. - Gaeta's appointment is seen as a strategic move to support Outset's next phase of growth and profitability goals [2]. Financial Guidance - Outset has reiterated its financial guidance for 2025, projecting revenues between $115 million and $125 million, with a non-GAAP gross margin expected to be in the high-30% range [2].